
|Videos|December 1, 2021
Clinical Implications of JAK Inhibitors
Author(s)Mary Scoviak, Managing Editor
In this video interview, James Q Del Rosso, DO, tackles the clinical impact of JAK Inhibitors and how to deal with patient concern.
Advertisement
James Q Del Rosso, DO, Research Director of JDR Dermatology Research in Las Vegas, Nevada and Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology & Cosmetic Surgery in Maitland, Florida, sits down with Dermatology Times® to discuss the practical challenges and opportunities available as JAK inhibitors move from pipeline to clinical practice.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: The Summer Skin Care "Shutdown"
2
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
3
ED Treatment Gaps Persist for Pediatric Atopic Dermatitis
4
Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD
5











